Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 4/20 | 0.41 |
| ▸ | GABRD | O14764 | 4/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.41 |
| ▸ | GABRE | P78334 | 4/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28157960 | 0.96 | — | — | |
| Acetic Acid SCHEMBL670655 | 0.96 | FFAR3 (0.58) | FFAR3LCKFYNSLC7A5TP53 | |
| Acetic Acid SCHEMBL11526476 | 0.89 | FFAR3 (0.50) | FFAR3LCKFYNSLC7A5TP53 | |
| Acetic Acid SCHEMBL6425236 | 0.89 | FFAR3 (0.50) | FFAR3LCKFYNSLC7A5TP53 | |
| Acetic Acid SCHEMBL44094 | 0.88 | — | — | |
| Acetic Acid SCHEMBL27717337 | 0.88 | FFAR3 (0.58) | FFAR3LCKFYNSLC7A5TP53 | |
| Alanine SCHEMBL28967983 | 0.86 | SLC7A5 (0.50) | FFAR3LCKFYNSLC7A5TP53 | |
| Alanine SCHEMBL28967982 | 0.86 | SLC7A5 (0.50) | FFAR3LCKFYNSLC7A5TP53 | |
| Acetic Acid SCHEMBL4292108 | 0.85 | FFAR3 (0.54) | FFAR3LCKFYNSLC7A5TP53 | |
| Acetic Acid SCHEMBL6051117 | 0.85 | FFAR3 (0.54) | FFAR3LCKFYNSLC7A5TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080050762-A1 | METHODS AND COMPOSITIONS FOR COUPLED LUMINESCENT ASSAYS | COREY MICHAEL J | 2008-02-28 | — | — | US | disclosed |
| US-6811990-B1 | RAPID/FLEXIBLE MEASUREMENT OF CELL CYTOTOXICITY AND/OR PROLIFERATION; ENZYMATIC ACTIVITY COUPLED TO PRODUCTION OF HIGH-ENERGY MOLECULE (ATP) WHICH SERVES AS A SUBSTRATE FOR ILLUMINATION BY A LUCIFERASE; PHOSPHATASES | Corey, Michael J. | 2004-11-02 | — | — | US | disclosed |
| US-20030190368-A1 | METHODS OF DIAGNOSIS AND TRIAGE USING CELL ACTIVATION MEASURES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-09 | — | — | US | disclosed |
| EP-1062323-A2 | METHODS OF DIAGNOSIS AND TRIAGE USING CELL ACTIVATION MEASURES | Cell Activation, Inc. (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999046367-A2 | METHODS OF DIAGNOSIS AND TRIAGE USING CELL ACTIVATION MEASURES | CELL ACTIVATION, INC. (US) | 1999-09-16 | — | — | WO | disclosed |
| EP-0270217-B1 | BLEACH-FIXING SOLUTION HAVING GOOD PROCESSING PERFORMANCE AND METHOD FOR PROCESSING LIGHT-SENSITIVE MATERIAL USING THE SAME | KONICA CORPORATION (JP) | 1993-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030190368-A1 | METHODS OF DIAGNOSIS AND TRIAGE USING CELL ACTIVATION MEASURES | SERPINB1, PLAT, SERPINE1 | FFAR3 2945/4885LCK 1076/4885FYN 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.